55 completed, 19 recruiting, 19 terminated, 14 unknown. 73 Phase 2, 46 Phase 1, 23 Phase 3, 1 Early Phase 1, 1 Phase 4.
Follow IFL protocol: new trials by email Literature Review of IFL protocol trials Research Report on IFL protocol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Evaluate the Safety and Activity of GDC-7035 With Anti-Cancer Therapies in Participants With KRAS G12D-Mutated Unresectable Advanced or Metastatic Colorectal Cancer or Pancreatic Ductal Adenocarcinoma GDC-7035, Panitumumab, mFOLFOX6 - Colorectal Neoplasms, Pancreatic Ductal Adenocarcinoma | Phase 1 | Not yet recruiting | Genentech, Inc. | 388 | 2026-10-31 | 2026-10-13 |
| EMB-01 in Combination With Chemotherapy for Unresectable or Metastatic Colorectal Cancer EMB-01, Irinotecan, TAS-102 - Unresectable/Metastatic Colorectal Cancer | Phase 1 | Recruiting | Shanghai EpimAb Biotherapeutics Co., Ltd. | 120 | 2026-09-30 | 2026-10-16 |
| Testing Ivonescimab in Combination With Chemotherapy in Patients With Metastatic Colorectal Cancers Without Liver Metastases Ivonescimab, Bevacizumab, FOLFIRI Protocol - Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | UNICANCER | 130 | 2026-08-31 | 2026-05-19 |
| Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1) Petosemtamab, Cetuximab, FOLFIRI - Left-sided Colorectal Cancer | Phase 3 | Recruiting | Genmab | 960 | 2026-08-11 | 2026-10-06 |
| A Study of ZG006 for Injection Versus Investigator-Selected Chemotherapy in Participants With Advanced Neuroendocrine Carcinoma ZG006, 5-fluorouracil, Calcium folinate and Irinotecan - Neuroendocrine Carcinoma | Phase 3 | Not yet recruiting | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | 240 | 2026-07-01 | 2026-05-19 |
| Oncolytic Virus (H101) + SBRT + Chemotherapy + Targeted Therapy + Immunotherapy for Unresectable CRLM SBRT, PD-1 Antibody, H101 - CRC, Liver Metastasis Colon Cancer | Phase 2 | Not yet recruiting | Jun Huang | 114 | 2026-06-01 | 2026-04-28 |
| FOLFIRI and Bevacizumab With or Without Pelareorep for Second-Line Treatment of Metastatic RAS-Mutated, Microsatellite-Stable Colorectal Cancer Bevacizumab, FOLFIRI, Pelareorep - Ras-mutated Metastatic Colorectal Cancer, mCRC | Phase 2 | Recruiting | Oncolytics Biotech | 60 | 2026-04-30 | 2026-10-27 |
| ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer SOC (Standard of care), Bevacizumab, Cetuximab - Dynamic Tumor Resistance, Metastatic Colorectal Cancer | Early Phase 1 | Recruiting | M.D. Anderson Cancer Center | 100 | 2026-04-22 | 2026-10-14 |
| A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation KST-6051, Gemcitabine/nab-paclitaxel, Cetuximab - KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC) | Phase 1 | Recruiting | Kestrel Therapeutics, Inc. | 545 | 2026-04-21 | 2026-10-15 |
| A Study to Evaluate the Efficacy and Safety of Inavolisib When Administered in Combination With Bevacizumab and FOLFOX or FOLFIRI as First Line Therapy in Participants With Colorectal Cancer Inavolisib, Bevacizumab, FOLFOX - Colorectal Cancer | Phase 2 | Withdrawn | Hoffmann-La Roche | 2026-02-01 | 2026-02-09 | |
| A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Bevacizumab in Combination With Chemotherapy in Participants With Previously Untreated, Unresectable, or Metastatic Colorectal Cancer Pumitamig, FOLFOX, FOLFIRI - Untreated, Unresectable, or Metastatic Colorectal Cancer | Phase 2 / Phase 3 | Recruiting | Bristol-Myers Squibb | 990 | 2025-12-31 | 2026-10-23 |
| AK112 Plus FOLFIRI Versus Bevacizumab Plus FOLFIRI as Second-line Treatment of MSS/pMMR Metastatic Colorectal Cancer AK112, FOLFIRI, Bevacizumab - Colorectal Cancer, Ivonescimab | Phase 2 | Not yet recruiting | Sun Yat-sen University | 130 | 2025-08-10 | 2025-06-15 |
| Trial of ProAgio in Advanced/Metastatic Colorectal Cancer ProAgio, FOLFIRI, Bevacizumab - Advanced Colorectal Cancer, Metastatic Colorectal Cancer | Phase 1 | Suspended | University of Alabama at Birmingham | 27 | 2025-07-17 | 2026-10-02 |
| Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial) FLOT, FOLFOX, FOLFIRI - Gastroesophageal Adenocarcinoma | Phase 1 | Recruiting | University of California, Irvine | 20 | 2025-06-27 | 2026-03-10 |
| Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based Chemotherapy Niraparib, FOLFIRI, Ipilimumab - Pancreatic Adenocarcinoma Metastatic | Phase 2 | Recruiting | Abramson Cancer Center at Penn Medicine | 68 | 2025-05-07 | 2026-10-13 |
| A Study of PHST001 in Advanced Solid Tumors PHST001, Paclitaxel, Topotecan - Advanced Solid Tumors, Ovarian Cancer | Phase 1 | Recruiting | Pheast Therapeutics | 426 | 2025-03-31 | 2026-10-05 |
| A Study of JNJ-89402638 for Metastatic Colorectal and Gastric Cancers JNJ-89402638, Bevacizumab, FOLFOX - Colorectal Neoplasms, Gastrointestinal Neoplasms | Phase 1 | Recruiting | Janssen Research & Development, LLC | 260 | 2024-10-15 | 2026-09-25 |
| Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab. encorafenib + cetuximab + FOLFIRI - Colorectal Carcinoma, Colorectal Neoplasms | Phase 2 | Recruiting | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 25 | 2024-06-03 | 2025-02-12 |
| Study of Onvansertib in Combination With FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab Versus FOLFIRI and Bevacizumab or FOLFOX and Bevacizumab for First-Line Treatment of Metastatic Colorectal Cancer in Adult Participants With a KRAS or NRAS Mutation Onvansertib, FOLFIRI, Bevacizumab - Metastatic Colorectal Cancer, CRC | Phase 2 | Active not recruiting | Cardiff Oncology | 110 | 2024-02-27 | 2026-06-16 |
| A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation INCB161734, Cetuximab, Retifanlimab - Solid Tumors | Phase 1 | Recruiting | Incyte Corporation | 710 | 2024-01-04 | 2026-07-22 |
Showing 20 of 126. Sign in to see all of them.
Colorectal Neoplasms (84) · Colonic Neoplasms (19) · Neoplasm Metastasis (18) · Rectal Neoplasms (15) · Neoplasms (13) · Stomach Neoplasms (7) · Carcinoma, Non-Small-Cell Lung (5) · Lung Neoplasms (5) · Ovarian Neoplasms (5) · Pancreatic Neoplasms (5) · Gastrointestinal Neoplasms (4) · Breast Neoplasms (3) · Carcinoma, Neuroendocrine (3) · Carcinoma, Renal Cell (3) · Endometrial Neoplasms (3)
Amgen (7) · AbbVie (4) · Cardiff Oncology (4) · Federation Francophone de Cancerologie Digestive (3) · Fudan University (3) · Genentech, Inc. (3) · Hoffmann-La Roche (3) · EMD Serono (2) · Eisai Inc. (2) · Incyte Corporation (2) · Merck Sharp & Dohme LLC (2) · Novartis Pharmaceuticals (2) · OncoMed Pharmaceuticals, Inc. (2) · Ruijin Hospital (2) · UNC Lineberger Comprehensive Cancer Center (2)
United States (55) · Spain (23) · France (20) · China (19) · Italy (19) · Germany (13) · Australia (12) · Canada (11) · United Kingdom (11) · Belgium (10) · South Korea (10) · Japan (8) · Israel (6) · Singapore (6) · Czechia (5)
Harish Dave (2) · Roberto Labianca, MD (2) · Abi Vainstein-Haras (1) · Alan Venook, MD (1) · Alberto Zaniboni, MD (1)
PMID 22070868, PMID 39475591, PMID 16356309, PMID 17553204, PMID 22000810, PMID 22576338, PMID 23361051, PMID 23493136, PMID 23955585, PMID 24905030, PMID 25287828, PMID 25627002, PMID 25772756, PMID 26049686, PMID 26341920, PMID 26861604, PMID 28497402, PMID 28632865, PMID 29627309, PMID 30080723, PMID 30679026, PMID 30840064, PMID 31042420, PMID 31221542, PMID 31300973, PMID 31378656, PMID 31408415, PMID 31515083, PMID 31548349, PMID 31902066, PMID 32766143, PMID 32921581, PMID 33264544, PMID 33812497, PMID 34315767, PMID 34646387, PMID 35191428, PMID 35202974, PMID 35366831, PMID 35427471, PMID 35467243, PMID 35484400, PMID 36067452, PMID 36369901, PMID 36720090, PMID 36739879, PMID 36860319, PMID 37337155, PMID 37535388, PMID 38036720
2025 (4), 2023 (3), 2008 (2), 2014 (2), 2015 (2), 2016 (2), 2018 (2), 2009 (1), 2019 (1), U10CA037447 (1)